The limits of segmental dichotomy: rethinking how we classify and compare minimally invasive liver resections [0.03%]
亚段式肝切除的局限性：重新思考我们如何分类和比较微创肝切除术
Víctor Lopez-Lopez,Cecilia Maina,Ricardo Robles-Campos
Víctor Lopez-Lopez
Acute cholecystitis in older adults with multimorbidity: does surgery offer better outcomes? [0.03%]
多病共存老年人急性胆囊炎患者外科手术的疗效如何？
Anaïs Tribolet,Sophie Chopinet
Anaïs Tribolet
Beyond precision: why time and human judgment still matter in the era of autonomous surgery [0.03%]
超越精准的时代：自主手术时代的时机与人判思维依然重要的原因分析
Xiaokun Chen,Shunda Du
Xiaokun Chen
Matthieu Sarabi,Pascal Artru
Matthieu Sarabi
Performance of major liver resection for gallbladder cancer-a western retrospective single center cohort study [0.03%]
一项西方单中心回顾性队列研究：肝切除术治疗胆囊癌的疗效分析
Constantin Scholz,Maria Hoppe-Lotichius,Arndt Weinmann et al.
Constantin Scholz et al.
Background: Gallbladder cancer (GBCa) is a rare disease in western countries and surgery remains the state of art, given the tumor is technically resectable. However, data for major liver resection in patients with advanc...
Never change a winning team-liver stiffness measurement and platelet count as key surrogates for clinically significant portal hypertension [0.03%]
利器为何要更换？肝脏弹性测定和血小板计数是临床显著门脉高压的理想替代标志
Georg Semmler,Mathias Jachs,Mattias Mandorfer
Georg Semmler
Rethinking resectability: the case for neoadjuvant treatment in resectable pancreatic cancer [0.03%]
重新定义可切除性：局部可切除胰腺癌新辅助治疗的必要性
Kai Tai Derek Yeung,Ricky Harminder Bhogal
Kai Tai Derek Yeung
Comprehensive treatment and surgical features of giant hepatic hemangioma with Kasabach-Merritt syndrome in an adult [0.03%]
成人Kasabach-Merritt综合征巨大肝血管瘤的综合治疗及手术特点
Yongqi Deng,Weikang Liu,Yu Zhu et al.
Yongqi Deng et al.
Rethinking the classical hepatic inflow occlusion time in hepatectomy for hepatocellular carcinoma under new circumstances [0.03%]
肝癌肝切除术再思考肝脏经典血流阻断时间（新情况）
Xuehai Jia,Gang Xu,Li Jiang
Xuehai Jia
Survival impact of conversion therapy for Barcelona Clinic Liver Cancer (BCLC) stage B and C hepatocellular carcinoma-a propensity score matching analysis [0.03%]
巴塞罗那临床肝癌B期和C期肝细胞癌转换治疗方法生存影响的倾向性评分匹配分析
Karin K Y Ho,Chi Leung Chiang,Tiffany Wong et al.
Karin K Y Ho et al.